This phase 2 randomized clinical trial examines the treatment regimen of mFOLFOXIRI plus cetuximab followed by either cetuximab or bevacizumab for patients with RAS and BRAF wild-type metastatic colorectal cancer.
from Cancer via ola Kala on Inoreader http://ift.tt/2EsF0iB
via IFTTT
Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου